logo-loader
viewMaxCyte Inc

MaxCyte to collaborate with leading infectious disease institute once again

The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease

immune system
CGD is an inherited genetic disorder that impairs the function of the immune system

MaxCyte, Inc. (LON:MXCT) is to continue its collaboration with one of the world’s leading infectious disease institutes after it signed a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAD).

The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s Flow Electroporation gene-correction platform.

WATCH: MaxCyte' boss 'confident of providing long-term treatment' for CGD patients

“We are delighted to continue our collaboration with NIAID which is leveraging MaxCyte's expertise in developing a new generation of genome editing therapy for CGD patients,” said President and chief executive Doug Doerfler.

“We believe that this work will validate the use of our platform for developing gene-editing therapies via rapid, cost-effective manufacturing.”

Chronic granulomatous disease

CGD is an inherited genetic disorder that impairs the function of the immune system and leads to ongoing and often severe bacterial infections.

It affects around one in 250,000 people across the globe and is currently only treatable through high-risk treatments such as bone marrow transplants.

Shares edged 2% higher in morning trade to 257.5p.

Quick facts: MaxCyte Inc

Price: 107.2499 GBX

AIM:MXCT
Market: AIM
Market Cap: £61.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read